Understand the source comparison
Best Peptides for Rheumatoid Arthritis: Research Comparison
Before reviewing individual peptide mechanisms, understand that research applications differ fundamentally from therapeutic use. The table below compares investigational compounds studied in laboratory models. Not approved treatments. BPC-157 Growth factor upr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before reviewing individual peptide mechanisms, understand that research applications differ fundamentally from therapeutic use. The table below compares investigational compounds studied in laboratory models. Not approved treatments.
- BPC-157
- Growth factor upregulation (VEGF, bFGF). Promotes angiogenesis and cartilage synthesis
- Moderate. 8+ rodent studies show 40–60% inflammation reduction and preserved cartilage in induced arthritis models
- 200–500 mcg/kg in animal studies
- Subcutaneous injection near affected joints or intraperitoneal
- Strongest evidence for tissue repair pathways; limited human trial data; mechanism supports cartilage protection rather than immune suppression
- TB-500
- Actin regulation and immune cell migration control via thymosin beta-4 signaling
- Moderate. 5+ studies demonstrate reduced synovial infiltration and improved mobility scores in arthritis models
- 2–10 mg/kg in preclinical protocols
- Subcutaneous or intramuscular injection
- Complementary to BPC-157; targets inflammatory cell trafficking; long administration period (8–12 weeks) required for structural changes
- Thymalin
- T-cell differentiation and immune tolerance restoration through thymic hormone mimicry
- Moderate to Strong. Human trial data shows 25–35% disease activity reduction when combined with methotrexate
- 5–20 mg total dose in published human studies
- Intramuscular injection
- Only peptide with published human RA trial data; modulates autoimmune response without broad immunosuppression; regulatory effects on CD4/CD8 ratios
- KPV
- NF-κB inhibition. Blocks inflammatory gene transcription at cellular level
- Preliminary. 3 rodent studies show 40–50% TNF-α reduction; minimal human data
- 1–5 mg total dose in animal models
- Subcutaneous or oral (low bioavailability oral)
- Small size allows intracellular access; localized anti-inflammatory action; limited long-term safety data; oral formulations poorly absorbed
- Epitalon
- Telomerase activation and cellular senescence modulation. Theoretical immune system rejuvenation
- Weak for RA specifically. Primarily studied for aging and longevity; indirect immune effects theorized
- 5–10 mg in aging research protocols
- Subcutaneous injection
- Mechanism doesn't directly target RA pathology; speculative application based on immune aging theories; insufficient evidence for joint-specific effects